Comprehensive genetic testing for neurological cancers
Supporting patient care through molecular and cytogenetic testing
Mayo Clinic is recognized worldwide for providing care for complex diseases, including brain tumors. With rapid technological advancements and medical discoveries, the standard approach to genetic testing is evolving. Mayo Clinic Laboratories is at the leading edge of testing innovation and offers both MayoComplete next-generation sequencing (NGS) and chromosomal microarray testing to complement standard morphological and histological assessment.
In a clinical study of adult glioma patients, comprehensive molecular and cytogenetic analysis resulted in significant — and sometimes unexpected — patient impact.
Clinical relevance: Findings in glioma patients
In a Mayo Clinic study of adult glioma patients, comprehensive molecular and cytogenetic analysis resulted in a significant positive impact on patients. Of 400 patients seen, 75% received diagnostic, prognostic, and/or predictive information.
of patients received one or more clinically actionable findings as a result of comprehensive molecular and cytogenetic testing
of cases reported diagnostic findings
of cases reported prognostic findings
of cases reported predictive findings
NGS analysis to detect mutations and rearrangements
Our NGS panel is part of our suite of MayoComplete NGS panels. It evaluates mutations and rearrangements in 160 genes, including most abnormalities described by the World Health Organization 20211 classifications. Our panel (Mayo ID: NONCP) includes assessment of mutations in 89 genes and rearrangements in 81 genes, including 104 fusions and 29 transcript variants.
NONCP | Neuro-Oncology Expanded Gene Panel with Rearrangement, Tumor
New gene panel enhances brain tumor profiles
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Chromosomal microarray to detect copy number variants
Chromosomal microarray provides high-resolution assessment of copy number variations across the genome. According to published guidelines, when these abnormalities are found in diffuse astrocytic gliomas, IDH wild-type, the tumor should be considered as having molecular features of glioblastoma.2 Copy number variations can also further clarify or support diagnosis and provide information useful for prognosis.
CMAPT | Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded
Chromosomal microarray better informs brain tumor diagnosis
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.
Testing to predict therapy response
MGMT promoter methylation status has prognostic value for glioblastoma patients and can assist in predicting therapeutic response.
MGMT | MGMT Promoter Methylation, Tumor